Table 2.
Participant characteristics of the post-exclusion cohort
| Clozapine group (n = 94) | Control group (n = 98) | |
|---|---|---|
| Age, years: mean (range) | 44.4 (22.0–78.0) | 50.4 (21.6–78.0) |
| Gender, men:women | 64:30 | 54:44 |
| Dual antipsychotic treatment, n (%) | 29 (30.9) | 11 (11.2) |
| Duration of antipsychotic use, years: median (range) | 8 (0.1–20) | 7 (0.1–44) |
| Current smoking, n (%) | 57 (60.6) | 55 (56.1) |
| Diabetes, n (%) | 19 (20.2) | 16 (16.3) |
| Chronic obstructive pulmonary disorder/asthma, n (%) | 12 (12.7) | 16 (16.3) |
| Alcohol intake, units per week: mean (range) | 5.3 (0–60) | 6.0 (0–68) |
| Primary psychiatric diagnosis, n | ||
| Schizophrenia | 87 | 58 |
| Schizoaffective disorder | 1 | 5 |
| Bipolar | 0 | 11 |
| Psychosis | 0 | 15 |
| Depression | 0 | 3 |
| Personality disorder | 2 | 2 |
| Anxiety disorder | 0 | 2 |
| Electronic record incomplete | 4 | 2 |
| Antibiotic courses in 12 months, n (%) | ||
| No courses | 57 (60.6) | 62 (63.3) |
| 1–5 courses | 32 (34.0) | 35 (35.7) |
| >5 courses | 5 (5.3) | 1 (1.0) |